COSCIENS Biopharma Completes Share Capital Amendment
COSCIENS Biopharma's (CSCI.TO) one for 150 share consolidation and a following share split took effect on Friday. COSCIENS said it competed the share consolidation and an immediate subsequent split of shares on the basis of 50 shares for every one post-consolidation share. Shareholders who held less than 150 shares as of the close of business on Thursday are entitled to a cash payment of US$1.60 in exchange for their pre-consolidation shares, the company said. COSCIENS said the shares are expected to begin trading on the Toronto Stock Exchange on a post-share capital amendment basis within two business days of the effective date under the same trading symbol. COSCIENS subsidiary Ceapro is focused on developing f natural, plant-based ingredients derived from oats and other renewable plant resources for personal care, cosmetic, human and animal health industries.
COSCIENS Biopharma's (CSCI.TO) one for 150 share consolidation and a following share split took effect on Friday.
COSCIENS said it competed the share consolidation and an immediate subsequent split of shares on the basis of 50 shares for every one post-consolidation share.
Shareholders who held less than 150 shares as of the close of business on Thursday are entitled to a cash payment of US$1.60 in exchange for their pre-consolidation shares, the company said.
COSCIENS said the shares are expected to begin trading on the Toronto Stock Exchange on a post-share capital amendment basis within two business days of the effective date under the same trading symbol.
COSCIENS subsidiary Ceapro is focused on developing f natural, plant-based ingredients derived from oats and other renewable plant resources for personal care, cosmetic, human and animal health industries.